Searched for
BIOCON TARGET PRICE
Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- I-Sec maintains Sell on Biocon, revises target price to Rs 270ICICI Securities maintains a 'Sell' call on Biocon, setting a revised target price of Rs 270. Despite a projected earnings CAGR of 91.6% dr...
- Buy Biocon, target price Rs 351: Axis SecuritiesAxis Securities recommends a Buy call on Biocon, setting a target price of Rs 351, indicating a potential 10% upside. The recommendation is...
- Stock Radar: Is Biocon losing momentum after hitting a fresh 52-week high in January 2025? Here’s what chart suggestsBiocon Ltd, in the pharma sector, breaks out from a 3-4 month consolidation, reaching a fresh high in January 2025. Experts suggest traders...
- Stock Radar: Biocon offers fresh buying opportunity; stock hits 52-week high in JanuaryBiocon stock hit a 52-week high of Rs 400 on January 20, 2025, after reversing losses above the 200-DMA in December. The breakout from a 4-...
- Motilal Oswal Financial Services upgrades Biocon to Buy, target price Rs 430Motilal Oswal Financial Services has recommended a buy on Biocon, targeting a price of Rs 430. The company, a leader in the pharmaceuticals...
- Biocon shares surge over 4% after Malaysia unit gets clearance from the USFDABiocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated. This followed a...
- Stock Radar: Biocon stock price breaks out from upper band of a Symmetrical Triangle; should you buy?Biocon Ltd has broken out of the Symmetrical Triangle formation on daily charts, suggesting a potential rise in stock price. Experts advise...
- Biocon shares zoom 4% as Jefferies upgrades to "hold" amid positive news inflow, sets Rs 400 targetBiocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concern...
- Buy Biocon, target price Rs 266: Sharekhan by BNP ParibasBiocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 26389.19 Crore) operating in Pharmaceuticals secto...
- Buy Biocon, target price Rs 365: JM FinancialGiven the multiple near-term levers, enviable biosimilars pipeline, strengthening of leadership teams, favourable valuation and marquee inv...
- Buy Biocon, target price Rs 395: JM FinancialBiocon Ltd., incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 31515.75 Crore) operating in Pharmaceuticals ...
- Buy Biocon, target price Rs 390: ICICI DirectBiocon Ltd., incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 39559.77 Crore) operating in Pharmaceuticals ...
- Buy Biocon, target price Rs 460: GeojitBiocon Ltd., incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 48780.38 Crore) operating in Pharmaceuticals ...
- Buy Biocon, target price Rs 390: Axis SecuritiesBiocon Ltd., incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 41870.93 Crore) operating in Pharmaceuticals ...
- Can Serum deal provide a booster dose to Biocon's target price?The Serum alliance would give Biocon Biologics' access to 100 million doses of vaccines per annum for 15 years with commercialisation right...
- Hold Biocon, target price Rs 410: ICICI DirectBiocon Ltd. key Products/Revenue Segments include Bio Pharmaceuticals, Other Operating Revenue, Waste and Sale of services for the year end...
Load More
